PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1515384
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1515384
Soft Tissue Sarcoma Market size was valued at USD 2,876.32 Million in 2023, expanding at a CAGR of 5.4% from 2024 to 2032.
Soft tissue sarcoma is a form of cancer originating in soft tissues like muscles, tendons, fat, lymph and blood vessels, and nerves. While they can develop in any part of the body, they are frequently located in the arms, legs, chest, and abdomen. With around 50 distinct types, identifying soft tissue sarcomas can pose a challenge. While some types predominantly affect adults, others are more common in children. The most common form of treatment is surgical removal, although radiation therapy and chemotherapy may also be recommended depending on the tumor's size, nature, location, and aggressiveness.
Soft Tissue Sarcoma Market- Market Dynamics
Need for continued research to better comprehend this disease to propel market demand
The expansion of the soft tissue sarcoma treatment market is chiefly propelled by the aberrant activity of specific genes governing cell division and growth. These genes, termed oncogenes, may undergo mutations or activation within soft tissue sarcoma cells, resulting in unchecked growth and rapid proliferation. Additionally, soft tissue sarcoma cells may produce high levels of growth factors, which are signaling molecules that promote cell growth and division. Although soft tissue sarcoma is considered a rare type of cancer, it is nonetheless a serious and life-threatening disease that should not be underestimated. Despite its lower prevalence compared to other types of cancer, soft tissue sarcoma still affects a significant number of people worldwide. Moreover, the fact that the causes of soft tissue sarcoma are not fully understood underscores the need for continued research to better comprehend this disease and develop more effective treatment strategies.
Soft Tissue Sarcoma Market- Key Insights
As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 5.4% over the forecast period (2024-2032)
Based on Treatment Type segmentation, Chemotherapy was predicted to show maximum market share in the year 2023
Based on End User segmentation, Hospitals were the leading type in 2023
Based on region, North America was the leading revenue generator in 2023
The Global Soft Tissue Sarcoma Market is segmented based on Treatment Type, Route of Administration, Distribution Channel, End User, and Region.
The market is divided into five categories based on Treatment Type: Targeted Therapy, Chemotherapy, Anti-Angiogenesis Drugs, Radiation Therapy, and Others. Chemotherapy currently dominates the treatment landscape in the soft tissue sarcoma market due to its longstanding efficacy and broad application across various sarcoma subtypes. Despite the emergence of targeted therapies and other advanced treatments, chemotherapy remains a cornerstone because of its ability to target rapidly dividing cancer cells systemically, making it suitable for both localized and metastatic disease. The versatility of chemotherapy regimens allows for their use in combination with other treatments such as surgery and radiation, thereby enhancing overall treatment effectiveness. Additionally, chemotherapy's established protocols and relatively lower costs compared to newer therapies contribute to its dominance in the market.
The market is divided into four categories based on End Users: Hospitals, Homecare, Speciality Centres, and Others. Hospitals serve as the primary end-users in the soft tissue sarcoma market, largely due to their comprehensive resources and capabilities in managing complex cancer treatments. Hospitals offer multidisciplinary care, which is crucial for sarcoma patients who often require a combination of surgery, chemotherapy, radiation, and supportive care. The presence of specialized oncologists, advanced diagnostic tools, and the ability to manage side effects and complications make hospitals the preferred setting for both initial and ongoing treatment. Furthermore, hospitals are often centers for clinical trials and advanced research, offering patients access to cutting-edge therapies and a higher standard of care.
Soft Tissue Sarcoma Market- Geographical Insights
Geographically, this market is widespread in the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business. The North American market is anticipated to register the largest market share during the forecast period, building on its leading revenue position in 2023. According to the American Cancer Society, an estimated 12,390 individuals were diagnosed with soft tissue sarcoma and associated cancers in 2016. Key factors driving market revenue growth include the high incidence rate of soft tissue sarcomas, increasing awareness of this condition, a growing focus on healthcare, and a well-established healthcare infrastructure.
In the competitive soft tissue sarcoma (STS) market, major players engage in strategic partnerships to enhance their offerings. By joining forces with other pharmaceutical firms, research institutions, or academic centers, companies can leverage their combined expertise, resources, and technologies to drive innovation and develop new treatments or diagnostic tools. These collaborations may also facilitate the sharing of data and knowledge, accelerating the pace of research and development. Additionally, partnerships can expand companies' market reach and enable them to access new geographic regions or patient populations. The demand for efficient therapies has grown alongside an increased incidence rate of tumors in general. Consequently, multinational corporations are investing a substantial portion of their earnings into research and development to create innovative pharmaceuticals. Several items connected to advanced medication delivery systems are awaiting FDA approval. It is anticipated that the rising demand for advanced drugs to treat gallbladder tumors will further drive market expansion.
In December 2020, the FDA granted an orphan drug designation to Moeculin Biotech's annamycin for soft tissue sarcoma.
In October 2020, Rafael Pharmaceuticals announced receiving an FDA grant of an Orphan Drug designation to CPI-613 (devimistat) indicated to treat soft tissue sarcoma. These designations underscore the importance of developing novel treatments for this challenging disease and highlight the ongoing efforts within the pharmaceutical industry to address unmet medical needs in soft tissue sarcoma.
GLOBAL SOFT TISSUE SARCOMA MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHT
Genentech USA
Pfizer, Inc.
Eli Lilly and Company
Bristol-Myers Squibb
Hoffmann-La Roche Ltd.
Johnson & Johnson, Inc.
GlaxoSmithKline
Teva Pharmaceuticals
Celgene Corporation
Others